Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The Symptom Inventory Disability-Specific Short Forms for Multiple Sclerosis: Reliability and Factor Structure.
Novartis updates US label on Gilenya® following discussions with the FDA
Epistasis and immunity: the role of genetic interactions in autoimmune diseases.
Insight into the role of CRMP2 (collapsin response mediator protein 2) in T lymphocyte migration: The particular context of virus infection.
Anti-integrin therapy for multiple sclerosis.
Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy.
1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization.
Long-term TENS treatment decreases cortical motor representation in multiple sclerosis.
Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.
IFN-β alters neurotrophic factor expression in T cells isolated from multiple sclerosis patients - implication of novel neurotensin/NTSR1 pathway in neuroprotection.
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
Quantitative proton density mapping: correcting the receiver sensitivity bias via pseudo proton densities.
The role of mitochondria in axonal degeneration and tissue repair in MS.
Overview of treatment options in multiple sclerosis.
Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review.
The natural course of clinically isolated syndrome in pediatric patients.
Update on biomarkers in neuromyelitis optica.
1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis.
Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function.
[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
From injection therapies to natalizumab: views on the treatment of multiple sclerosis.
Oligoclonal band and multiple sclerosis risk in monosymptomatic optic neuritis patients: a retrospective study of 84 patients.
Is multiple sclerosis a proresolution deficiency disorder?
Studies of EN-1639A (naltrexone): a new narcotic antagonist.
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.

Pages